--- title: "Sino Biopharm Unit LaNova Unveils Promising ADC Data at AACR 2026" type: "News" locale: "en" url: "https://longbridge.com/en/news/283566957.md" description: "Sino Biopharmaceutical's unit LaNova Medicines presented promising preclinical data on two antibody-drug conjugates, LM-364 and LM-338, at the AACR Annual Meeting 2026. These ADCs target solid tumors, with LM-364 showing strong antitumor activity and a favorable safety profile, progressing towards an IND filing with the U.S. FDA. LM-338 demonstrated high target specificity, indicating potential for future pipeline expansion. Analysts rate Sino Biopharmaceutical (HK:1177) stock as a Buy with a price target of HK$8.70, reflecting confidence in its oncology-focused innovations." datetime: "2026-04-21T22:37:46.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/283566957.md) - [en](https://longbridge.com/en/news/283566957.md) - [zh-HK](https://longbridge.com/zh-HK/news/283566957.md) --- # Sino Biopharm Unit LaNova Unveils Promising ADC Data at AACR 2026 ### Claim 30% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Sino Biopharmaceutical ( (HK:1177) ) has issued an announcement. Sino Biopharmaceutical’s wholly owned unit LaNova Medicines has showcased new preclinical data on two antibody-drug conjugates, LM-364 and LM-338, at the American Association for Cancer Research Annual Meeting 2026, underscoring its push into next-generation oncology biologics. The programs target solid tumors with technologies aimed at improving tumor selectivity and safety profiles, reinforcing the group’s positioning in high-value cancer therapeutics. LM-364, a Nectin-4 tumor microenvironment-activated ADC, demonstrated strong antitumor activity across multiple patient-derived xenograft models and a favorable safety profile in animal studies, and has already progressed to an IND filing with the U.S. FDA ahead of a planned first-in-human trial in 2026. LM-338, designed as a potential first-in-class ADC against the tumor-specific STn glycan antigen, showed high target specificity and efficient internalization, signaling future pipeline expansion in solid tumor indications if later-stage data confirm these preclinical results. The most recent analyst rating on (HK:1177) stock is a Buy with a HK$8.70 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page. **More about Sino Biopharmaceutical** Sino Biopharmaceutical Limited is a China-focused pharmaceutical company engaged in the research, development, manufacturing, and commercialization of innovative therapies, with a strong emphasis on oncology. Through subsidiaries such as LaNova Medicines, it develops advanced antibody-drug conjugates and other targeted treatments for solid tumors and other cancers. **Average Trading Volume:** 69,721,589 **Technical Sentiment Signal:** Buy **Current Market Cap:** HK$110.3B Learn more about 1177 stock on TipRanks’ Stock Analysis page. ### Related Stocks - [01177.HK](https://longbridge.com/en/quote/01177.HK.md) - [560600.CN](https://longbridge.com/en/quote/560600.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [589720.CN](https://longbridge.com/en/quote/589720.CN.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [159615.CN](https://longbridge.com/en/quote/159615.CN.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [516820.CN](https://longbridge.com/en/quote/516820.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [588860.CN](https://longbridge.com/en/quote/588860.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [159929.CN](https://longbridge.com/en/quote/159929.CN.md) ## Related News & Research - [Onco-Innovations Announces Inka Health Collaborative Research to Advance Oncology Evidence Generation | ONNVF Stock News](https://longbridge.com/en/news/285274936.md) - [Sino Biopharm Sets Hybrid AGM, Seeks Fresh Share Issue Mandate](https://longbridge.com/en/news/284532331.md) - [GenFleet Asserts Independent IP for Pan RAS Inhibitor GFH276 Amid Sector Dispute](https://longbridge.com/en/news/284312081.md) - [Grand Pharmaceutical Moves to Adopt New Bye-Laws Aligned With HK Paperless Regime](https://longbridge.com/en/news/284576690.md) - [07:55 ETSupport Egg Quality and Ovulation with Nature's Bounty® New Fertility Supplement*](https://longbridge.com/en/news/285200796.md)